Category: Uncategorized

KUALA LUMPUR, Nov 15 (Bernama) — In conjunction with World Sight Day 2021 and awareness for eyecare Be Quinn Global (BeQ), a health and beauty company, joined hands with the Malaysian Association for the Blind (MAB) and Kakiseni, the arts and culture hub, organising a unique art workshop for the visually impaired.

The workshop which was attended by 11 visually impaired members of MAB saw the participants get hands-on with tactile elements and in touch with their creative side through clay art with a focus on cultivating sensory stimulation and expression.

Commenting on the initiative and World Sight Day, Loreen Ling the founder of BeQ said, “As a brand with a keen focus on eye care, we are passionate about World Sight Day and its celebration. So when it came to this year’s occasion, we knew we wanted to do something special and what could be more meaningful than bringing joy and creative freedom to the visually impaired.”

The benefits of art have long been touted for the visually impaired with art being recognized as an important outlet for the development of dexterity, self-confidence, critical thinking skills, and self-awareness. With their heightened sense of touch, the visually impaired are more in tune with tactile art. This acts as a conduit for the participants to improve their pictorial literacy whilst also expressing themselves.

“At MAB, we are not only focused on providing for and empowering our community of visually impaired but also committed to general public outreach to cultivate a better understanding of the challenges and unique circumstances our members experience daily. Beyond enriching our members, today’s workshop is also important as it provides others with a unique insight into how the visually impaired perceive the world and in turn portray it through their art. We hope on this special occasion of World Sight Day, more people will get invested in the wellbeing of Malaysia’s visually impaired,” said George Thomas, Chief Executive Officer at the Malaysian Association for the Blind.

Alongside the workshop, BeQ has also donated RM5,000 to MAB to assist with the day-to-day facilitation and management of the organization’s activities and initiatives that look to enrich and empower its members.

BeQ’s flagship product is an eye care product, Lumina Eye Vitamin, that aims to enhance vision and provide essential nutrients that can help maintain eye health and good macular function. Formulated in Japan with three main ingredients – Lutein & Zeaxanthin, Blue-Green Algae, and Prune Extract, Lumina Eye Vitamin addresses common vision issues including short-sightedness, amblyopia (lazy eye), visual fatigue, and eye strain.

SOURCE: Be Quinn Global

http://mrem.bernama.com/viewsm.php?idm=41570

KUALA LUMPUR, Nov 15 — The 5th Belt and Road Teenager Maker Camp and Teacher Workshop kicked off in Nanning recently.

Co-sponsored by the China Association for Science and Technology, the Ministry of Science and Technology of the People’s Republic of China, the Chongqing Municipal People’s Government and the Guangxi Zhuang Autonomous Region, the event was organised by the Guangxi Zhuang Autonomous Region Science and Technology Association.

Guangxi Science and Technology Museum implemented the event, according to a statement.

Launched in September, the event will last until November-end, featuring a combination of online and offline activities.

The online platform introduced the ‘Belt and Road Teenagers in the Same Class’, bringing together 10 science and technology classrooms and experts from nine countries. Science popularisation expert, Professor David performed a science show online and pioneered a novel approach to science education in countries along the Belt and Road.

The event also featured the online activity ‘Dialogue with Scientists’ and provided more than 100 science and technology courses and science popularisation materials such as ‘Space Maker’, ‘Low Carbon and Energy Saving’, and ‘Images of Science’.

Guangxi University and Nanning No.3 Middle School put on an online live show to showcase Guangxi’s embroidered ball, Zhuang dance, Guilin landscape and other scenic spots through videos and VR.

The event attracted one million teachers and students from 53 countries, regions and international organisations.

— BERNAMA

KUALA LUMPUR, Nov 15 (Bernama) — Taiwantrade.com is presenting a Senior Care and Wellness Online Showcase from November to January 2022, featuring high-quality products and suppliers in the professional field of aged-care, healthcare, and wellness industries from Taiwan.

Among the featured products on display are medical braces & supports, healthcare & rehabilitation equipment, compression socks, wheelchair retractors, hydrocolloid wound dressing, haircare & salon products, etc.

With the pandemic still raging, the Senior Care and Wellness Online Showcase provides buyers with easy and safe access to a wide array of quality products from Taiwan, according to a statement.

The online showcase includes nearly 1,000 products from eight excellent Taiwanese suppliers, visitors can not only browse the 360-degree image and video to get a closer look at product details but also use the sourcing services to connect with suppliers online.

IRUFA, an expert of 3D elastic knitted spacer fabric braces, presents a full line of sporting and medical supports, magnetic therapy, and far-infrared ray therapy products.

GRACE CARE is a professional supplier of braces and supports, orthopedic rehabilitation equipment, and sports protective equipment, while MISHENG specialises in the design and manufacturing of healthcare products such as electrotherapy treatment garments, electrical stimulators, and the moist heating pad.

Also joining the showcase are LE SHIN, presenting medical socks and regular compression stockings in different lengths and materials, and TRIDA, showcasing its collection of hydrocolloid wound dressing products such as hydrocolloid plaster, acne pad, footpad, and adhesive bandage.

Other excellent companies such as OZER, ARTIST COSMETICS, and JUN KUANG are also presenting their top-of-the-line products for senior care and wellness.

With more than 70,000 quality suppliers and a database of over 660,000 products, Taiwantrade.com is a one-stop sourcing platform that offers reliable, trustworthy, and efficient sourcing services for buyers to connect with Taiwanese suppliers and industries.

It is operated by the Taiwan External Trade Development Council (TAITRA). More details at https://www.taiwantrade.com.

— BERNAMA

· The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week (11/11/2021)
· Celltrion continues to discuss supply agreements with regulatory agencies and contractors in more than 30 countries in Europe, Asia and LATAM to accelerate global access to regdanvimab
· The use of regdanvimab across the Republic of Korea is rapidly increasing to address the ongoing outbreaks

INCHEON, South Korea, Nov 15 (Bernama-BUSINESS WIRE) — Celltrion Group announced today that the European Commission (EC) has approved Regkirona (regdanvimab, CT-P59), one of the first monoclonal antibody treatments granted marketing authorisation from the European Medicines Agency (EMA). The EC granted marketing authorisation for adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The decision from the EC follows a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on November 11^th, 2021.^¹

“Today’s achievement, coupled with CHMP positive opinion for regdanvimab, underscores our ongoing commitment to addressing the world’s greatest health challenges,” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “Typically, the recommendations from the CHMP are passed on to the EC for rapid legally binding decisions within a month or two, however, given the unprecedented times, we have received the EC approval within a day. As part of our global efforts to accelerate access, we have been communicating with the governments and contractors in 30 countries in Europe, Asia and LATAM. We will continue working with all key stakeholders to ensure COVID-19 patients around the world have access to safe and effective treatments.”

Monoclonal antibodies are proteins designed to attach to a specific target, in this case the spike protein of SARS-CoV-2, which works to block the path the virus uses to enter human cells. The EC approval is based on the global Phase III clinical trial involving more than 1,315 people to evaluate the efficacy and safety of regdanvimab in 13 countries including the U.S., Spain, and Romania. Data showed regdanvimab significantly reduced the risk of COVID-19 related hospitalisation or death by 72% for patients at high-risk of progressing to severe COVID-19.

Emergency use authorisations are currently in place in Indonesia and Brazil, and the monoclonal antibody treatment is fully approved in the Republic of Korea. In the U.S., regdanvimab has not yet been approved by the Food and Drug Administration (FDA), but the company is in discussion with the FDA to submit applications for an Emergency Use Authorisation (EUA).

As of November 12^th, 2021, more than 22,587 people have been treated with regdanvimab in 129 hospitals in the Republic of Korea.

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About regdanvimab (CT-P59)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre- clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralise the wild type and mutant variants of concern. In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global Phase I and Phase II/III clinical trials of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild-to-moderate symptoms of COVID-19.^² Celltrion also has recently commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging variants of SARS-CoV-2.

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare’s management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

^¹ European Medicines Agency. COVID-19: EMA recommends authorisation of two monoclonal antibody medicines. Available at https://www.ema.europa.eu/en/news/covid-19-ema-recommends-authorisation-two-monoclonal-antibody-medicines [Last accessed November 2021].
^² Celltrion Data on file

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211114005312/en/

Contact

Holly Barber
hbarber@hanovercomms.com
+44 (0) 07759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

Source : Celltrion Healthcare

–BERNAMA

KUALA LUMPUR, Nov 3 — Mary Kay Inc has announced sponsorship of a project to improve water security in Monterrey, in partnership with The Nature Conservancy.

The project, led by a group of female entrepreneurs, focuses on restoring local species of trees in the surrounding areas of the city of Monterrey to help maintain ecosystem services, decrease the risk and impact of floods in the city, and restore the degraded forests in the region.

“As an advocate for women’s leadership, we are very proud to see how these local leaders are steering the change in our community, playing a critical role in the preservation of our most valuable natural resource and nurturing a sustainable future for thousands of families in the region,” said Mary Kay Inc Chief Operating Officer, Deborah Gibbins in a statement.

The City of Monterrey is currently home to four million people. Located in an area naturally prone to extreme hydrometeorological events such as hurricanes and flooding, the city often faces serious water supply challenges.

Near the city is the Cumbres de Monterrey National Park, a protected natural reserve that accounts for about 60 per cent of the water that comes to the city.

The area also supports the control of heavy stormwater runoff which impacts people, local livestock, and urban infrastructure. To maintain environmental resiliency, vegetation cover needs to be restored and the production of native plants in nurseries must be ensured.

Mary Kay and The Nature Conservancy are supporting a group of female entrepreneurs in the Laguna Sanchez community who are leading a unique initiative to combat these challenges.

This group of landowners is producing several native species of plants to be used for reforestation projects in the national park. The project will not only address the rising need for these species, but also improve livelihoods for their families and rural community members.

To help tell the story of empowerment and natural conservation of Angelica and Mujeres Unidas Para La Conservación de Laguna de Sanchez, Mary Kay Inc has produced a short film in partnership with The Nature Conservancy.

More details at http://www.marykayglobal.com.

— BERNAMA